BioNexus Gene Lab Corp. Accumulated Other Comprehensive Income
BioNexus Gene Lab Corp. (BGLC) had Accumulated Other Comprehensive Income of -$127.21 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-14
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$127.21K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$98.85K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$120.75K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$112.55K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$127.21K 10-Q · filed 2026-08-14 |
| 2026-03-31 | -$98.85K 10-Q · filed 2026-05-15 |
| 2025-12-31 | -$120.75K 10-Q · filed 2026-08-14 |
| 2025-09-30 | -$112.55K 10-Q · filed 2025-11-14 |
| 2025-06-30 | -$115.76K 10-Q · filed 2025-08-18 |
| 2025-03-31 | -$482.84K 10-Q · filed 2025-05-15 |
| 2024-12-31 | -$555.00K 10-K · filed 2026-04-14 |
| 2024-09-30 | -$162.05K 10-Q · filed 2024-11-15 |
| 2024-06-30 | -$884.74K 10-Q · filed 2024-08-14 |
| 2024-03-31 | -$887.20K 10-Q · filed 2024-05-15 |
| 2023-12-31 | -$677.29K 10-K · filed 2025-04-15 |
| 2023-09-30 | -$800.60K 10-Q/A · filed 2024-03-26 |
| 2023-06-30 | -$781.99K 10-Q · filed 2023-08-16 |
| 2023-03-31 | -$448.10K 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$409.06K 10-K · filed 2024-04-16 |
| 2022-09-30 | -$807.39K 10-Q · filed 2022-11-14 |
| 2022-06-30 | -$486.80K 10-Q · filed 2022-08-15 |
| 2022-03-31 | -$169.04K 10-Q · filed 2022-05-16 |
| 2021-12-31 | -$100.26K 10-K · filed 2023-03-31 |
| 2021-09-30 | -$139.19K 10-Q · filed 2021-11-15 |
| 2021-06-30 | -$82.25K 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$74.78K 10-Q · filed 2021-05-18 |
| 2020-12-31 | $133.68K 10-K · filed 2022-04-06 |
| 2020-09-30 | -$33.35K 10-Q/A · filed 2020-11-09 |
| 2020-06-30 | -$55.29K 10-Q · filed 2020-08-11 |
| 2020-03-31 | -$58.78K 10-Q · filed 2020-05-08 |
| 2019-12-31 | -$17.10K 10-K · filed 2021-03-30 |
| 2019-09-30 | -$38.23K 10-Q · filed 2019-11-14 |
| 2019-06-30 | -$27.43K 10-Q · filed 2019-08-09 |
| 2019-03-31 | -$9.83K 10-Q · filed 2019-05-15 |
| 2018-12-31 | -$26.98K 10-K · filed 2020-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |